Innovation The Centerpiece In Mixed Japan 2019 Outlook
2019 has already brought one industry-shaking event in Japan with the formal completion of the Takeda-Shire deal. But how will this play out and what else can we expect in this key market over the next year?
You may also be interested in...
The antibody-drug conjugate being evaluated by Astellas and Seattle Genetics has posted “remarkable” positive top-line results in locally advanced or metastatic urothelial cancer, with a US BLA submission expected later in 2019.
The latest group of new product approvals in Japan includes the first marketing clearances worldwide for fracture-reducing osteoporosis antibody romosozumab and a stem cell-based therapy for spinal cord injury, as well as two new Daiichi drugs and Pfizer's lung cancer therapy dacomitinib.
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.